Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Occupational risk of salmonellosis and campylobacteriosis: a nationwide population-based registry study.

Duijster JW, Franz E, Neefjes JJC, Mughini-Gras L.

Occup Environ Med. 2019 Sep;76(9):617-624. doi: 10.1136/oemed-2019-105868.

PMID:
31413185
2.

Photo-crosslinking of clinically relevant kinases using H89-derived photo-affinity probes.

Stolze SC, Liu N, Wijdeven RH, Tuin AW, van den Nieuwendijk AM, Florea BI, van der Stelt M, van der Marel GA, Neefjes JJ, Overkleeft HS.

Mol Biosyst. 2016 May 24;12(6):1809-17. doi: 10.1039/c6mb00257a.

PMID:
27138522
3.

A catalogue of treatment and technologies for malignant pleural mesothelioma.

Schunselaar LM, Quispel-Janssen JM, Neefjes JJ, Baas P.

Expert Rev Anticancer Ther. 2016;16(4):455-63. doi: 10.1586/14737140.2016.1162100. Review.

PMID:
26943000
4.

Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules.

Berkers CR, de Jong A, Schuurman KG, Linnemann C, Meiring HD, Janssen L, Neefjes JJ, Schumacher TN, Rodenko B, Ovaa H.

J Immunol. 2015 Nov 1;195(9):4085-95. doi: 10.4049/jimmunol.1402455. Epub 2015 Sep 23.

5.

Cowpox virus protein CPXV012 eludes CTLs by blocking ATP binding to TAP.

Luteijn RD, Hoelen H, Kruse E, van Leeuwen WF, Grootens J, Horst D, Koorengevel M, Drijfhout JW, Kremmer E, Früh K, Neefjes JJ, Killian A, Lebbink RJ, Ressing ME, Wiertz EJ.

J Immunol. 2014 Aug 15;193(4):1578-89. doi: 10.4049/jimmunol.1400964. Epub 2014 Jul 14.

6.

Ubiquitin-based probes prepared by total synthesis to profile the activity of deubiquitinating enzymes.

de Jong A, Merkx R, Berlin I, Rodenko B, Wijdeven RH, El Atmioui D, Yalçin Z, Robson CN, Neefjes JJ, Ovaa H.

Chembiochem. 2012 Oct 15;13(15):2251-8. doi: 10.1002/cbic.201200497. Epub 2012 Sep 25.

7.

Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.

Souwer Y, Chamuleau ME, van de Loosdrecht AA, Tolosa E, Jorritsma T, Muris JJ, Dinnissen-van Poppel MJ, Snel SN, van de Corput L, Ossenkoppele GJ, Meijer CJ, Neefjes JJ, Marieke van Ham S.

Br J Haematol. 2009 May;145(3):334-43. doi: 10.1111/j.1365-2141.2009.07625.x. Epub 2009 Feb 24.

PMID:
19245431
8.

Varicellovirus UL 49.5 proteins differentially affect the function of the transporter associated with antigen processing, TAP.

Koppers-Lalic D, Verweij MC, Lipińska AD, Wang Y, Quinten E, Reits EA, Koch J, Loch S, Marcondes Rezende M, Daus F, Bieńkowska-Szewczyk K, Osterrieder N, Mettenleiter TC, Heemskerk MH, Tampé R, Neefjes JJ, Chowdhury SI, Ressing ME, Rijsewijk FA, Wiertz EJ.

PLoS Pathog. 2008 May 30;4(5):e1000080. doi: 10.1371/journal.ppat.1000080.

9.

Puromycin-sensitive aminopeptidase limits MHC class I presentation in dendritic cells but does not affect CD8 T cell responses during viral infections.

Towne CF, York IA, Neijssen J, Karow ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Neefjes JJ, Rock KL.

J Immunol. 2008 Feb 1;180(3):1704-12.

10.

Profiling proteasome activity in tissue with fluorescent probes.

Berkers CR, van Leeuwen FW, Groothuis TA, Peperzak V, van Tilburg EW, Borst J, Neefjes JJ, Ovaa H.

Mol Pharm. 2007 Sep-Oct;4(5):739-48. Epub 2007 Aug 21.

PMID:
17708652
11.

A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates.

Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, Koppers-Lalic D, Croft NP, Neefjes JJ, Rickinson AB, Wiertz EJ.

J Exp Med. 2007 Aug 6;204(8):1863-73. Epub 2007 Jul 9.

12.

Multidrug resistance-associated protein 9 (ABCC12) is present in mouse and boar sperm.

Ono N, Van der Heijden I, Scheffer GL, Van de Wetering K, Van Deemter E, De Haas M, Boerke A, Gadella BM, De Rooij DG, Neefjes JJ, Groothuis TA, Oomen L, Brocks L, Ishikawa T, Borst P.

Biochem J. 2007 Aug 15;406(1):31-40.

13.

A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo.

Verdoes M, Florea BI, Menendez-Benito V, Maynard CJ, Witte MD, van der Linden WA, van den Nieuwendijk AM, Hofmann T, Berkers CR, van Leeuwen FW, Groothuis TA, Leeuwenburgh MA, Ovaa H, Neefjes JJ, Filippov DV, van der Marel GA, Dantuma NP, Overkleeft HS.

Chem Biol. 2006 Nov;13(11):1217-26.

14.

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ.

J Exp Med. 2006 May 15;203(5):1259-71. Epub 2006 Apr 24.

15.

Cutting edge: HLA-B27 acquires many N-terminal dibasic peptides: coupling cytosolic peptide stability to antigen presentation.

Herberts CA, Neijssen JJ, de Haan J, Janssen L, Drijfhout JW, Reits EA, Neefjes JJ.

J Immunol. 2006 Mar 1;176(5):2697-701.

16.

Leucine aminopeptidase is not essential for trimming peptides in the cytosol or generating epitopes for MHC class I antigen presentation.

Towne CF, York IA, Neijssen J, Karow ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Neefjes JJ, Rock KL.

J Immunol. 2005 Nov 15;175(10):6605-14.

17.

MHC class I alleles and their exploration of the antigen-processing machinery.

Groothuis TA, Griekspoor AC, Neijssen JJ, Herberts CA, Neefjes JJ.

Immunol Rev. 2005 Oct;207:60-76. Review.

PMID:
16181327
18.

Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains.

Kuipers HF, Biesta PJ, Groothuis TA, Neefjes JJ, Mommaas AM, van den Elsen PJ.

Hum Immunol. 2005 Jun;66(6):653-65.

PMID:
15993711
19.

Bovine herpesvirus 1 interferes with TAP-dependent peptide transport and intracellular trafficking of MHC class I molecules in human cells.

Koppers-Lalic D, Rychlowski M, van Leeuwen D, Rijsewijk FA, Ressing ME, Neefjes JJ, Bienkowska-Szewczyk K, Wiertz EJ.

Arch Virol. 2003 Oct;148(10):2023-37.

PMID:
14551822
20.

From fixed to FRAP: measuring protein mobility and activity in living cells.

Reits EA, Neefjes JJ.

Nat Cell Biol. 2001 Jun;3(6):E145-7. Review.

PMID:
11389456
21.

Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site.

Beekman NJ, van Veelen PA, van Hall T, Neisig A, Sijts A, Camps M, Kloetzel PM, Neefjes JJ, Melief CJ, Ossendorp F.

J Immunol. 2000 Feb 15;164(4):1898-905.

22.

Accurate intracellular localization of HLA-DM requires correct spacing of a cytoplasmic YTPL targeting motif relative to the transmembrane domain.

Potter PK, Copier J, Sacks SH, Calafat J, Janssen H, Neefjes JJ, Kelly AP.

Eur J Immunol. 1999 Dec;29(12):3936-44.

23.

Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope.

Vierboom MP, Feltkamp MC, Neisig A, Drijfhout JW, ter Schegget J, Neefjes JJ, Melief CJ, Kast WM.

J Immunother. 1998 Nov;21(6):399-408.

PMID:
9807734
24.

Proteasome activity limits the assembly of MHC class I molecules after IFN-gamma stimulation.

Benham AM, Neefjes JJ.

J Immunol. 1997 Dec 15;159(12):5896-904.

PMID:
9550386
25.
26.

Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells.

Tan MC, Mommaas AM, Drijfhout JW, Jordens R, Onderwater JJ, Verwoerd D, Mulder AA, van der Heiden AN, Scheidegger D, Oomen LC, Ottenhoff TH, Tulp A, Neefjes JJ, Koning F.

Eur J Immunol. 1997 Sep;27(9):2426-35.

PMID:
9341789
27.

Mannose receptor mediated uptake of antigens strongly enhances HLA-class II restricted antigen presentation by cultured dendritic cells.

Tan MC, Mommaas AM, Drijfhout JW, Jordens R, Onderwater JJ, Verwoerd D, Mulder AA, van der Heiden AN, Ottenhoff TH, Cella M, Tulp A, Neefjes JJ, Koning F.

Adv Exp Med Biol. 1997;417:171-4.

PMID:
9286356
28.

Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines.

Izquierdo MA, Neefjes JJ, Mathari AE, Flens MJ, Scheffer GL, Scheper RJ.

Br J Cancer. 1996 Dec;74(12):1961-7.

29.

How cells instruct the immune system to carry out their elimination.

Fernandez-Borja M, Neefjes JJ.

Biochem Soc Trans. 1996 Nov;24(4):1039-43. Review. No abstract available.

PMID:
8968508
30.

Antigen presentation by MHC class I and II molecules.

Neefjes JJ.

Immunobiology. 1996 Oct;195(4-5):456-60. Review. No abstract available.

PMID:
8933150
31.
32.

Translocation of long peptides by transporters associated with antigen processing (TAP).

Koopmann JO, Post M, Neefjes JJ, Hämmerling GJ, Momburg F.

Eur J Immunol. 1996 Aug;26(8):1720-8.

PMID:
8765012
33.

Antigen processing by the class I pathway.

Benham AM, Neefjes JJ.

Biochem Soc Trans. 1995 Aug;23(3):664-9. Review. No abstract available.

PMID:
8566439
34.

Major histocompatibility complex class II compartments in human B lymphoblastoid cells are distinct from early endosomes.

Peters PJ, Raposo G, Neefjes JJ, Oorschot V, Leijendekker RL, Geuze HJ, Ploegh HL.

J Exp Med. 1995 Aug 1;182(2):325-34.

35.

MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells.

Kleijmeer MJ, Ossevoort MA, van Veen CJ, van Hellemond JJ, Neefjes JJ, Kast WM, Melief CJ, Geuze HJ.

J Immunol. 1995 Jun 1;154(11):5715-24.

PMID:
7751623
36.

Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences.

Neisig A, Roelse J, Sijts AJ, Ossendorp F, Feltkamp MC, Kast WM, Melief CJ, Neefjes JJ.

J Immunol. 1995 Feb 1;154(3):1273-9.

PMID:
7822796
37.

Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments.

Sanderson F, Kleijmeer MJ, Kelly A, Verwoerd D, Tulp A, Neefjes JJ, Geuze HJ, Trowsdale J.

Science. 1994 Dec 2;266(5190):1566-9.

PMID:
7985027
38.

Peptide size selection by the major histocompatibility complex-encoded peptide transporter.

Momburg F, Roelse J, Hämmerling GJ, Neefjes JJ.

J Exp Med. 1994 May 1;179(5):1613-23.

39.

Targeting major histocompatibility complex class II molecules to the cell surface by invariant chain allows antigen presentation upon recycling.

Nijenhuis M, Calafat J, Kuijpers KC, Janssen H, de Haas M, Nordeng TW, Bakke O, Neefjes JJ.

Eur J Immunol. 1994 Apr;24(4):873-83.

PMID:
8149958
40.

Selectivity of MHC-encoded peptide transporters from human, mouse and rat.

Momburg F, Roelse J, Howard JC, Butcher GW, Hämmerling GJ, Neefjes JJ.

Nature. 1994 Feb 17;367(6464):648-51.

PMID:
8107849
41.

Peptide selection by MHC-encoded TAP transporters.

Momburg F, Neefjes JJ, Hämmerling GJ.

Curr Opin Immunol. 1994 Feb;6(1):32-7. Review.

PMID:
8172678
43.

Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter.

Neefjes JJ, Momburg F, Hämmerling GJ.

Science. 1993 Aug 6;261(5122):769-71. Erratum in: Science 1994 Apr 1;264(5155):16.

PMID:
8342042
44.

The assembly of H2-Kb class I molecules translated in vitro requires oxidized glutathione and peptide.

Bijlmakers MJ, Neefjes JJ, Wojcik-Jacobs EH, Ploegh HL.

Eur J Immunol. 1993 Jun;23(6):1305-13.

PMID:
8500526
45.
46.

Cell biology of antigen presentation.

Neefjes JJ, Momburg F.

Curr Opin Immunol. 1993 Feb;5(1):27-34. Review.

PMID:
7680870
47.

Phosphorylation of surface E-selectin and the effect of soluble ligand (sialyl Lewisx) on the half-life of E-selectin.

Smeets EF, de Vries T, Leeuwenberg JF, van den Eijnden DH, Buurman WA, Neefjes JJ.

Eur J Immunol. 1993 Jan;23(1):147-51.

PMID:
7678223
48.

E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro.

Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TM, Ahern TJ, Buurman WA.

Immunology. 1992 Dec;77(4):543-9.

49.

Distribution and elimination of the glycosidase inhibitors 1-deoxymannojirimycin and N-methyl-1-deoxynojirimycin in the rat in vivo.

Faber ED, Oosting R, Neefjes JJ, Ploegh HL, Meijer DK.

Pharm Res. 1992 Nov;9(11):1442-50.

PMID:
1475231
50.

HLA class I and II molecules present influenza virus antigens with different kinetics.

Kuijpers KC, van Kemenade FJ, Hooibrink B, Neefjes JJ, Lucas CJ, van Lier RA, Miedema F.

Eur J Immunol. 1992 Sep;22(9):2339-45.

PMID:
1516624

Supplemental Content

Loading ...
Support Center